Homology Medicines

United States
Altona, Illinois, United States, 02421

Company profile

Homology Medicines company profile

Homology Medicines, Inc. is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases with significant unmet medical needs by curing the underlying cause of the disease. Homology’s proprietary platform is designed to utilize its human hematopoietic stem cell-derived adeno-associated virus vectors (AAVHSCs) to precisely and efficiently deliver genetic medicines in vivo either through a gene therapy or nuclease-free gene editing modality across a broad range of genetic disorders. Homology has a management team with a successful track record of discovering, developing and commercializing therapeutics with a particular focus on rare diseases and a robust intellectual property portfolio with issued composition of matter patents in the United States for its suite of 15 AAVHSCs. Homology believes that its compelling preclinical data, scientific expertise, product development strategy, manufacturing capabilities and intellectual property position it as a leader in the development of genetic medicines.

Business identity

Operating status
Closed
Company type
For Profit
Employee range
101-250 employees
Revenue range
$0+
Founded
2015-01-01, Year

Headquarters

Postal code
02421
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
M And A
Funding rounds
3
Total equity funding
$187M
Last funding
Post IPO Equity / $60M / 2020-11-09
Last equity funding
Post IPO Equity / $60M
Investors
15
Lead investors
4
Founders
2
Articles
46
Exited on
2018-03-27

Founders and investors

Founders

Laura SmithSaswati Chatterjee

Lead investors

5AM VenturesARCH Venture PartnersDeerfieldPfizer Breakthrough Growth Initiative

Investors

5AM VenturesARCH Venture PartnersMaverick VenturesTemasek HoldingsVivo Capital